Getting to the Heart of Type 2 Diabetes Management: Practice Insights for Nurse Practitioners and Physician Assistants

Released On
March 22, 2019

Expires On
March 22, 2020

Media Type

Completion Time
60 minutes

Endocrinology, Primary Care, Cardiology

Type 2 Diabetes

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Creative Educational Concepts, Inc.


Supported by an independent education grant from AstraZeneca.

Credit Available

  • PAs — 1.0 Category 1 CME credits.
  • Nurse Practitioners — maximum of 1.0 contact hour(s). Includes 1.0 hour of pharmacology

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Nurse Practitioners and Physician Assistants who treat patients with type 2 diabetes.

Program Overview

Management strategies for cardiovascular risk in patients with type 2 diabetes (T2D) are rapidly evolving as cardiovascular outcome trial (CVOT) data with newer glucose-lowering therapies continues to emerge, presenting new opportunities for members of the healthcare team to improve care for patients with T2D. The goal of this educational activity is to provide nurse practitioners and physician assistants with updates on new and emerging CVOT data for glucose lowering therapies, assess clinical implications of CVOT results on real-world T2D treatment selection, review updated ADA guidelines for the management of T2D, and explore effective strategies to individualize T2D therapy and reduce cardiovascular risk.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the mechanisms linking diabetes, heart failure, and cardiovascular disease.
  • Compare and contrast new and emerging CVOT data for glucose lowering therapies and review current guideline recommendations for the management of T2D in patients with and without cardiovascular disease.
  • Examine available efficacy and safety data for glucose lowering therapies in T2D patients with, or at risk for, heart failure and cardiovascular disease.
  • Using a case-based approach, apply CVOT data and current guideline recommendations to individualize glucose lowering therapy and reduce cardiovascular risk in patients with T2D.


Mark W. Stolar, MD

Associate Professor of Clinical Medicine
Northwestern University School of Medicine
Chicago, Illinois

Joint Accreditation Statement

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Assistant Credit Designation Statement

CEC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Credit Designation Statement

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hour of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19023563. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Upon completion of a CE request form, statements of credit for physician assistants and nurse practitioners will be issued within 30 business days.

Disclosures of Conflicts of Interest

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


  • Adrienne Matson, PharmD: has no relevant financial relationships to disclose in relation to the content of this activity.


  • Mark Stolar, MD: has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer

  • Michael G. Clark, PhD, PA-C, MPAS, AACC, DFAAPA: has no relevant financial relationships to disclose in relation to the content of this activity.
  • Debra K. Moser, PhD, RN, FAAN: has no relevant financial relationships to disclose in relation to the content of this activity.

Disclosure of Unlabeled Use

This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

Method of Participation

To receive a statement of credit, you must:

  1. Read the target audience, learning objectives, and author disclosures
  2. Review the full content of the activity and reflect upon its teaching
  3. Complete the questions and evaluation at the end of the activity
  4. Have a passing score of 70% on the post-test (you will have two [2] opportunities to complete the post-test)


Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


It is the policy of CEC to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.

Contact Information

For CME questions, please contact: CEC at